Abstract
Overview
Introduction
The incidence of multiple myeloma is forecast to total 40,885 cases across the
seven major pharmaceutical markets in 2007. Current drug therapy is planned
around stem cell transplantation. The recent approval of three new
agents-Thalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and
Velcade (bortezomib; Millenium/Johnson & Johnson)-has significantly advanced
treatment.
Scope
- Multiple myeloma epidemiology, disease features and progress in current
treatment
- Remaining unmet needs in the treatment of multiple myeloma
- Research and analysis of the multiple myeloma pipeline with in-depth
clinical and commercial assessment of Phase III drug candidates
- Stakeholder opinions based on qualitative interviews with key opinion
leaders from the US and EU
Report Highlights
The approval of three new agents, Thalomid (thalidomide; Celgene), Revlimid
(lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson),
has significantly changed the MM treatment approach for both newly diagnosed
and relapsed/refractory disease.
Despite the recent advances in treatment, MM remains largely incurable as
disease relapse is inevitable. There remains a strong need for more
efficacious and tolerable drugs that affect new therapeutic targets and
enhance patient outcomes.
There is great opportunity for novel agents to enter the myeloma market as
patients often require multiple lines of therapy. Furthermore, the major
approach to myeloma drug therapy is the use of combined regimens. A drug that
shows potential synergistic activity with other approved or emerging drugs
would be well received.
Reasons to Purchase
- Gain an insight into the epidemiology trends and disease characteristics
of multiple myeloma
- Analyze the current status of multiple myeloma treatment and consider the
remaining unmet needs
- Acquire a detailed appreciation and impartial perspective of the multiple
myeloma pipeline and identify the key products in late-phase development
View Cart
